Is Vemlidy Safer for Kidneys Than Viread?
Yes, Vemlidy (tenofovir alafenamide, or TAF) shows better kidney safety than Viread (tenofovir disoproxil fumarate, or TDF) in clinical studies of chronic hepatitis B patients. TAF achieves similar antiviral efficacy with lower plasma tenofovir exposure—about 90% less—which reduces stress on kidneys and bones.[1][2]
How Do Kidney Risks Compare in Studies?
In phase 3 trials like GS-US-320-0108 and GS-US-320-0110, TAF patients had smaller declines in estimated glomerular filtration rate (eGFR) by creatinine: -0.6 mL/min vs. -2.5 mL/min for TDF after 48 weeks. Fewer TAF patients (1.2%) developed eGFR below 50 mL/min compared to 2.5% on TDF. Proximal tubulopathy events, like elevated proteinuria or phosphaturia, occurred less often with TAF (1.6% vs. 3.8%).[2][3]
Longer-term data from year 5 showed sustained benefits: TAF maintained eGFR stability while TDF users saw progressive drops, with 0.4% vs. 2.6% progressing to chronic kidney disease stage 3.[4]
Why Does TAF Spare Kidneys More?
TAF is a prodrug that converts to tenofovir mostly inside liver cells, keeping blood levels low. TDF circulates more freely, accumulating in kidney tubules and causing toxicity over time. This explains higher discontinuation rates for TDF due to renal issues (up to 8% in some HBV studies).[1][5]
Who Switches from Viread to Vemlidy?
Guidelines from AASLD and EASL recommend TAF over TDF for patients with baseline kidney impairment (eGFR <60 mL/min), those over 60, or with comorbidities like diabetes. Real-world data confirm fewer renal adverse events post-switch.[6][7]
What About Bone Safety Differences?
TAF also cuts bone risks: hip and spine density losses were 0.16% and 0.25% with TAF vs. 1.73% and 2.51% with TDF at 48 weeks. Fractures were rare but lower with TAF.[2]
Are There Exceptions or Ongoing Concerns?
Patients with severe kidney disease (eGFR <15 mL/min) need dose adjustments or avoidance for both, but TAF requires less adjustment. Rare cases of Fanconi syndrome persist with TAF, though far less than TDF. Monitor eGFR, urine protein, and phosphate regardless.[3][8]
[1]: Gilead Sciences prescribing information for Vemlidy
[2]: Agarwal K et al. N Engl J Med. 2018;378:2497-2508. NEJM link
[3]: FDA label comparison: Vemlidy vs. Viread. FDA Vemlidy
[4]: Lampertico P et al. J Hepatol. 2020;73:37-46. PubMed
[5]: Hill A et al. Antivir Ther. 2016;21:99-114. PubMed
[6]: AASLD Hepatitis B Guidance. Hepatology. 2018. AASLD
[7]: EASL 2017 Clinical Practice Guidelines. J Hepatol. 2017. EASL
[8]: DrugPatentWatch.com - Tenofovir patents and safety data. DrugPatentWatch